Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tenon Medical, Inc. (NASDAQ:TNON) announced plans to release its financial results for Q1 2023, concluding on March 31, 2023, after market close on May 9, 2023. A conference call will follow at 4:30 p.m. Eastern Time to discuss the results, including a Q&A session. Investors can join the call via dial-in numbers: 1-888-886-7786 (USA) or 1-416-764-8658 (International). The audio will be available for playback until May 23, 2023. Tenon Medical focuses on the Catamaran™ SI Joint Fusion System, which offers a less invasive approach to treat sacroiliac disorders. The company is set for a national launch of this system, targeting a significant market opportunity.
Tenon Medical (NASDAQ:TNON) reported a transformative year, concluding with a 423% revenue increase in Q4 2022, totaling $277,000, and a full-year revenue of $691,000, up 332%. Surgical procedures using the Catamaran System surged 386% in Q4 and 361% for the year. Despite these gains, the company reported a gross loss of $(207,000) in Q4 and $(641,000) for 2022. Operating losses jumped to $7.9 million in Q4 and $18.7 million for the year, impacted by a $3.6 million charge related to the termination of a national distribution agreement. Cash reserves stood at $8.6 million as of year-end, supporting ongoing operations.
Tennon Medical (NASDAQ:TNON) has successfully treated its first patient in the clinical study for the Catamaran SI Joint Fusion System. Conducted by Dr. Mark H. Stouffer at Zion Surgery Center on November 14, 2022, the study aims to evaluate the long-term effectiveness of this innovative system in addressing sacroiliac joint disorders. Patients will be monitored for pain scores and fusion rates over 24 months. The Catamaran design is expected to enhance patient outcomes by stabilizing the joint and facilitating fusion.
Tenon Medical reported a 197% increase in revenue year-over-year for Q3 2022, totaling $208,000. The company launched its Catamaran SI Joint Fusion System at the North American Spine Society meeting, engaging healthcare professionals with workshops and technical exhibits. Operating losses rose to $3.3 million, with a net loss of $3.2 million, compared to losses of $2.1 million and $2.3 million in Q3 2021. The company's cash reserves stand at $12.5 million, expected to support future growth initiatives.